Omega-3 Supplementation for Children with Learning Difficulties and Attention Deficit Disorder: Is it Beneficial?

Natan Gadoth

doi:10.1055/s-0039-1677726

Journal of Pediatric Neurology, Table of Contents

Journal of Pediatric Neurology 2020; 18(01): 001-006
DOI: 10.1055/s-0039-1677726

Review Article

Georg Thieme Verlag KG Stuttgart · New York

Omega-3 Supplementation for Children with Learning Difficulties and Attention Deficit Disorder: Is it Beneficial?

Authors

Natan Gadoth

¹Department of Neurology, Mayanei Hayeshua Medical Center, Bnie Barak, Israel

²Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Abstract

The use of “natural medicines,” food supplements, and in particular long-chain polyunsaturated fatty acids (omega-3/6) for a large variety of ailments including attention deficit hyperactivity disorder (ADHD) and other developmental behavioral disorders has dramatically increased in the past few years. In recent publications, doubts have been raised in regard to the benefits and risks of this form of treatment for ADHD. In this article, a short history of the way this treatment has evolved, its theoretical basis, and evidence-based data on the value of this popular supplementation will be reviewed.

Keywords

attention deficit hyperactivity disorder - omega-3 - omega-6 - long-chain polyunsaturated fatty acids - dietary supplements

Full Text

References

References
1 Weyandt LL, White TL, Gudmundsdottir BG. , et al. Neurocognitive, autonomic, and mood effects of Adderall: a pilot study of healthy college students. Pharmacy (Basel) 2018; 6 (03) E58
2 Guy RA. The history of cod liver oil as a remedy. Am J Dis Child 1923; 26: 112-116
3 Colquhoun I, Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children. Med Hypotheses 1981; 7 (05) 673-679
4 Horrobin DF, Manku MS. Possible role of prostaglandin E1 in the affective disorders and in alcoholism. BMJ 1980; 280 (6228): 1363-1366
5 Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998; 30 (03) 193-208
6 Mitchell EA, Aman MG, Turbott SH, Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. Clin Pediatr (Phila) 1987; 26 (08) 406-411
7 Stevens LJ, Zentall SS, Deck JL. , et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr 1995; 62 (04) 761-768
8 Stevens LJ, Zentall SS, Abate ML, Kuczek T, Burgess JR. Omega-3 fatty acids in boys with behavior, learning, and health problems. Physiol Behav 1996; 59 (4-5): 915-920
9 Stevens L, Zhang W, Peck L. , et al. EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors. Lipids 2003; 38 (10) 1007-1021
10 Parletta N, Niyonsenga T, Duff J. Omega-3 and omega-6 polyunsaturated fatty acid levels and correlations with symptoms in children with attention deficit hyperactivity disorder, autistic spectrum disorder and typically developing controls. PLoS One 2016; 11 (05) e0156432
11 Tinoco J. Dietary requirements and functions of alpha-linolenic acid in animals. Prog Lipid Res 1982; 21 (01) 1-45
12 Crupi R, Marino A, Cuzzocrea S. n-3 fatty acids: role in neurogenesis and neuroplasticity. Curr Med Chem 2013; 20 (24) 2953-2963
13 Hallahan B, Garland MR. Essential fatty acids and mental health. Br J Psychiatry 2005; 186 (04) 275-277
14 Kitajka K, Sinclair AJ, Weisinger RS. , et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc Natl Acad Sci U S A 2004; 101 (30) 10931-10936
15 Farquharson J, Cockburn F, Patrick WA, Jamieson EC, Logan RW. Infant cerebral cortex phospholipid fatty-acid composition and diet. Lancet 1992; 340 (8823): 810-813
16 Janssen CI, Kiliaan AJ. Long-chain polyunsaturated fatty acids (LCPUFA) from genesis to senescence: the influence of LCPUFA on neural development, aging, and neurodegeneration. Prog Lipid Res 2014; 53: 1-17
17 Clandinin MT, Chappell JE, Leong S, Heim T, Swyer PR, Chance GW. Extrauterine fatty acid accretion in infant brain: implications for fatty acid requirements. Early Hum Dev 1980; 4 (02) 131-138
18 Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res 1999; 56 (06) 565-570
19 Bos DJ, van Montfort SJ, Oranje B, Durston S, Smeets PA. Effects of omega-3 polyunsaturated fatty acids on human brain morphology and function: What is the evidence?. Eur Neuropsychopharmacol 2016; 26 (03) 546-561
20 Kemper KJ. Dietary supplements for attention-deficit/hyperactivity disorder--a fishy business?. J Pediatr 2001; 139 (02) 173-174
21 Abdelhamid AS, Brown TJ, Brainard JS. , et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018; 7: CD003177
22 Aung T, Halsey J, Kromhout D. , et al; Omega-3 Treatment Trialists' Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol 2018; 3 (03) 225-234
23 Gadoth N. On fish oil and omega-3 supplementation in children: the role of such supplementation on attention and cognitive dysfunction. Brain Dev 2008; 30 (05) 309-312
24 Kemper AR, Maslow GR, Hill S. , et al. Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment in Children and Adolescents. Report No.: 18–EHC005-EF. Rockville, (MD): Agency for Healthcare Research and Quality (US); ; 2018 January
25 Charach A, Dashti B, Carson P. , et al. Attention Deficit Hyperactivity Disorder: Effectiveness of Treatment in At-Risk Preschoolers; Long-Term Effectiveness in All Ages; and Variability in Prevalence, Diagnosis, and Treatment. Rockville, (MD): Agency for Healthcare Research and Quality (US); ; 2011 Oct. Report No. 12-EHC003-EF
26 Conners CK, Pitkanen J, Rzepa S. Conners Comprehensive Behavior Rating Scale. In: Kreutzer J, DeLuca J, Caplan B. , eds. Encyclopedia of Clinical Neuropsychology. New York: Springer; 2011: 678-680
27 Bard DE, Wolraich ML, Neas B, Doffing M, Beck L. The psychometric properties of the Vanderbilt attention-deficit hyperactivity disorder diagnostic parent rating scale in a community population. J Dev Behav Pediatr 2013; 34 (02) 72-82
28 Banaschewski T, Belsham B, Bloch MH. , et al. Supplementation with polyunsaturated fatty acids (PUFAs) in the management of attention deficit hyperactivity disorder (ADHD). Nutr Health 2018; 260106018772170
29 Omega 3 Market Analysis and Segment Forecasts to 2020. Grand View Research, Inc.; 2014. Available at: https://www.grandviewresearch.com/industry-analysis/omega-3-market . Accessed September 2, 2018
30 Abikoff H, Gallagher R, Wells KC. , et al. Remediating organizational functioning in children with ADHD: immediate and long-term effects from a randomized controlled trial. J Consult Clin Psychol 2013; 81 (01) 113-128
31 Anand P, Sachdeva A. Effect of poly unsaturated fatty acids administration on children with attention deficit hyperactivity disorder: a randomized controlled trial. J Clin Diagn Res 2016; 10 (09) OC01-OC05
32 Arcieri R, Germinario EA, Bonati M. , et al; Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. J Child Adolesc Psychopharmacol 2012; 22 (06) 423-431
33 Arnold LE, Disilvestro RA, Bozzolo D. , et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacol 2011; 21 (01) 1-19
34 Bai GN, Wang YF, Yang L, Niu WY. Effectiveness of a focused, brief psychoeducation program for parents of ADHD children: improvement of medication adherence and symptoms. Neuropsychiatr Dis Treat 2015; 11: 2721-2735
35 Gow RV, Hibbeln JR. Omega-3 fatty acid and nutrient deficits in adverse neurodevelopment and childhood behaviors. Child Adolesc Psychiatr Clin N Am 2014; 23 (03) 555-590
36 Kleiner AC, Cladis DP, Santerre CR. A comparison of actual versus stated label amounts of EPA and DHA in commercial omega-3 dietary supplements in the United States. J Sci Food Agric 2015; 95 (06) 1260-1267
37 Albert BB, Derraik JG, Cameron-Smith D. , et al. Fish oil supplements in New Zealand are highly oxidised and do not meet label content of n-3 PUFA. Sci Rep 2015; 5: 7928
38 Ritter JC, Budge SM, Jovica F. Quality analysis of commercial fish oil preparations. J Sci Food Agric 2013; 93 (08) 1935-1939
39 Mason RP, Sherratt SCR. Omega-3 fatty acid fish oil dietary supplements contain saturated fats and oxidized lipids that may interfere with their intended biological benefits. Biochem Biophys Res Commun 2017; 483 (01) 425-429
40 Jackowski SA, Alvi AZ, Mirajkar A. , et al. Oxidation levels of North American over-the-counter n-3 (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety. J Nutr Sci 2015; 4: e30
41 Berliner JA, Watson AD. A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005; 353 (01) 9-11
42 Gadoth N. Free radicals: their role in brain function and dysfunction. In: Armstrong D, Stratton RD. , eds. Oxidative Stress and Antioxidant Protection. Hoboken, NJ: Wiley-Blackwell; 2016: 23-38
43 John TE, Rebry RM, Yan KL, Rice BH, Rowe WJ. Measurements of environmental contaminants in a globally-representative sample of fish oil supplements. Nutrasource Diagnostics Inc. and Global Organization for EPA and DHA Omega-3s, USA
44 Chang CH, Tseng PT, Chen NY. , et al. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids 2018; 129: 1-12
45 NICE (National Institute for health Care Excellence, UK) guideline [NG87]. Published date: March 2018. Attention deficit hyperactivity disorder: Diagnosis and management. Available at: https://www.nice.org.uk/guidance/cg72 . Accessed September 2, 2018